PSA-velocity bei prostataerkrankungen

R. Thiel; J. D. Pearson; H. B. Carter

doi:10.1055/s-2008-1065255

PSA-velocity bei prostataerkrankungen

Translated title of the contribution: PSA velocity in diseases of the prostate

R. Thiel, J. D. Pearson, H. B. Carter

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence (<0.75 ng/ml/year) from distant metastasis (> 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.

Translated title of the contribution	PSA velocity in diseases of the prostate
Original language	German
Pages (from-to)	19-23
Number of pages	5
Journal	Aktuelle Urologie
Volume	29
Issue number	1
DOIs	https://doi.org/10.1055/s-2008-1065255
State	Published - Feb 1998

Keywords

Prostate specific antigen
Review
Velocity

ASJC Scopus subject areas

Urology

Access to Document

10.1055/s-2008-1065255

Fingerprint Dive into the research topics of 'PSA velocity in diseases of the prostate'. Together they form a unique fingerprint.

Cite this

@article{fa3c0e3fc9cf41ac9fd637d274481107,

title = "PSA-velocity bei prostataerkrankungen",

abstract = "Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence (<0.75 ng/ml/year) from distant metastasis (> 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.",

keywords = "Prostate specific antigen, Review, Velocity",

author = "R. Thiel and Pearson, {J. D.} and Carter, {H. B.}",

year = "1998",

month = feb,

doi = "10.1055/s-2008-1065255",

language = "German",

volume = "29",

pages = "19--23",

journal = "Aktuelle Urologie",

issn = "0001-7868",

publisher = "Georg Thieme Verlag",

number = "1",

}

TY - JOUR

T1 - PSA-velocity bei prostataerkrankungen

AU - Thiel, R.

AU - Pearson, J. D.

AU - Carter, H. B.

PY - 1998/2

Y1 - 1998/2

N2 - Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence (<0.75 ng/ml/year) from distant metastasis (> 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.

AB - Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence (<0.75 ng/ml/year) from distant metastasis (> 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.

KW - Prostate specific antigen

KW - Review

KW - Velocity

UR - http://www.scopus.com/inward/record.url?scp=0032361313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032361313&partnerID=8YFLogxK

U2 - 10.1055/s-2008-1065255

DO - 10.1055/s-2008-1065255

M3 - Article

AN - SCOPUS:0032361313

VL - 29

SP - 19

EP - 23

JO - Aktuelle Urologie

JF - Aktuelle Urologie

SN - 0001-7868

IS - 1

ER -

PSA-velocity bei prostataerkrankungen

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this